Loop Medical

Executive Summary

Loop Medical is a Swiss point-of-care diagnostics company founded in 2018 and headquartered in Lausanne. The company develops portable medical devices designed to deliver rapid, lab-quality diagnostic testing directly at the patient's bedside, enabling faster clinical decision-making. By miniaturizing complex diagnostic assays into a handheld format, Loop Medical addresses the growing demand for decentralized testing in hospitals, clinics, and remote settings. The platform leverages proprietary microfluidic and sensing technologies to run multiplexed assays with high accuracy and speed. While still at an early development stage, Loop Medical targets high-impact applications such as infectious disease detection, cardiac marker analysis, and chronic disease monitoring. The company's vision aligns with the global shift toward point-of-care testing, which is projected to grow significantly due to the need for rapid results and reduced healthcare costs. Loop Medical's competitive advantage lies in its ability to combine portability with laboratory-grade performance, a challenge that has hindered many prior point-of-care devices. The management team has a strong background in medical device development and diagnostics commercialization. However, given the company's early stage and limited public information, risks include technical scalability, regulatory clearance, and market adoption. Loop Medical is well-positioned to capture niche opportunities in emergency medicine and primary care, provided it secures adequate funding and achieves regulatory milestones. The company's success will depend on its ability to validate its technology through clinical studies and establish strategic partnerships with healthcare providers or diagnostic distributors.

Upcoming Catalysts (preview)

• Q3 2026Completion of Series A financing round70% success
• Q2 2027CE marking for lead product (multiplex infectious disease panel)55% success
• Q4 2026First strategic partnership with a hospital network for clinical validation50% success